Can Jisandai/Bingtongsha be cured after taking it for three months?

Epclusa, developed by Gilead, is an oral drug widely used to treat hepatitis C (HCV). It consists of two antiviral drugs, Sofosbuvir and Velpatasvir, which have broad-spectrum anti-hepatitis C virus (HCV) effects. Gisanda is widely used in the treatment of hepatitis C around the world and has been approved by health agencies in many countries as one of the standard drugs for the treatment of hepatitis C.

The course of treatment for hepatitis C is usually 12 weeksHowever, individual patients may choose to shorten or extend the treatment time based on different clinical responses and conditions. As to whether a three-month course of treatment can cure hepatitis C, the answer is usually yes. For most patients, especially those with HCV genotype 1, the cure rate of Jisandai after three months of treatment is quite high. Clinical studies show that after 12 weeks of treatment, more than 95% of patients can achieve a virological response, that is, a sustained state of viral suppression. At this time, the HCV RNA test in the patient's blood is negative, which means that the virus has been effectively eliminated and the patient may be cured.

However, the definition of cure does not solely rely on viral suppression during treatment but also requires long-term virological follow-up. After treatment is completed, doctors usually continue to monitor the patient's liver function and viral levels to confirm whether there is a recurrence of the virus. For the vast majority of patients, three months of treatment is effective in controlling and clearing the hepatitis C virus from the body, leading to cure, especially in those who have not received other anti-hepatitis C drugs.

It should be noted that the effectiveness of treatment is also affected by many factors, such as the patient's age, gender, liver health (such as the presence of cirrhosis), whether there are other chronic diseases, and whether there are HCV drug-resistant mutations, etc. Therefore, not all patients can be completely cured after three months of treatment, and individual patients may need to extend the treatment time, or the risk of viral recurrence may be discovered during subsequent monitoring.

Reference: https://www.epclusa.com/